A Huntington’s Breakthrough Hits a Very Real Wall

According to New Scientist, 2025 saw a pivotal breakthrough for Huntington’s disease, with an experimental gene therapy called AMT-130 showing it can slow the condition’s progression. In a late-stage trial by biotech company uniQure, a high dose given to 17 people slowed progression by about 75% on average over three years compared to an untreated group. The therapy, which delivers genetic instructions to block toxic protein production, is the first to ever show it can modify the disease. However, it requires a 12-to-18-hour surgery delivered deep into the brain, a procedure only a few global facilities can perform. Team member Sarah Tabrizi at University College London calls it a “giant step forward” but admits getting it to everyone will be “challenging.” In a setback, uniQure’s plan to submit for FDA approval in early 2026 is now unclear after the agency raised reservations about the study’s design in November.

The hope and the hurdle

Look, this is genuinely huge news. As Sarah O’Shea at Mount Sinai noted, the field has had so many setbacks. To finally see something that actively puts the brakes on this devastating disease? That’s the kind of result that changes the entire conversation for patients and families. It shifts the narrative from managing an inevitable decline to actually treating a condition. The 75% figure is staggering, almost too good to be true. But here’s the thing: that massive number comes with an equally massive caveat—the delivery method.

The delivery problem is everything

We have to talk about that surgery. A 12-to-18-hour procedure to inject a therapy directly into the brain is not just “invasive.” It’s a monumental logistical and medical barrier. Tabrizi points out that even in the US and UK, only a handful of centers could do it. And the cost? It would almost certainly be exorbitant. So you have a therapy that might work brilliantly for a tiny, tiny fraction of the people who need it. That’s the brutal reality of cutting-edge biotech. It’s why the team is already working on a next-gen version injected into the spinal fluid, which is in an early study now. But that’s years behind.

The FDA’s very valid questions

And then there’s the regulatory path. The FDA’s reservations, as noted in a uniQure statement, aren’t some bureaucratic nitpick. The trial didn’t have a concurrent control group—people who got a sham surgery for comparison. Instead, they used a database of untreated patients. That makes it really hard to rule out the placebo effect, or even just differences in how the two groups were monitored. I get why they did it. Who would volunteer for fake brain surgery? But it creates a real scientific problem. The FDA is basically saying, “Prove it.” CEO Matt Kapusta says they’re committed to working with the agency, but this uncertainty is a major cloud over the project.

What it all really means

So where does this leave us? Basically, with a classic tale of medical progress. A stunning scientific proof-of-concept crashes into the hard walls of practical medicine: delivery, access, cost, and regulatory proof. The hope this generates is real and important. It proves the mechanism can work. But the journey from a 17-person trial to an accessible treatment is a marathon, not a sprint. The next few years will be about simplifying the delivery and satisfying the regulators. The breakthrough is real, but the finish line just got moved a lot farther away.